ibrutinib,venetoclax
abbvie,janssen,roche
['cll', ' ibru']
 presents i+v data in high risk cll. no difference in outcomes regardless of p53/del17. now question is sequencing #ash22 
Assistant Professor at UNC Eshelman School of Pharmacy. #adherence, #leukemia, #globalhealth, #access, #impsci, #equity